mRNA-1018 for H5N8 / Moderna - LARVOL DELTA

A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults. (PubMed, Clin Infect Dis) - "Vaccine candidates were sufficiently well-tolerated and immunogenic. Further development of mRNA pandemic influenza vaccines is warranted for pandemic preparedness."

Journal • P1/2 data • Fatigue • Infectious Disease • Influenza • Pain • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1504 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1504 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1500 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases